Association between composite dietary antioxidant index and metabolic dysfunction associated steatotic liver disease: result from NHANES, 2017-2020

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: July 22, 2024

Background The development of metabolic dysfunction associated steatotic liver disease (MASLD) has been with lipid accumulation, oxidative stress, endoplasmic reticulum and lipotoxicity. Composite Dietary Antioxidant Index (CDAI) is a comprehensive score representing an individual intake various dietary antioxidants, including vitamin A, C, E, selenium, zinc, carotenoids. This study investigated the association between CDAI MASLD. Materials methods Clinical demographic data, as well ultrasound transient elastography measurements at baseline, were collected from National Health Nutrition Examination Survey 2017–2020 (NHANES 2017–2020). controlled attenuation parameter was utilized to diagnose presence hepatic steatosis categorize individuals into those without Liver stiffness measured by elastography, subjects classified advanced fibrosis. Results included 5,884 adults, whom 3,433 diagnosed MASLD, resulting in weighted prevalence 57.3%. After adjusting for covariates, odds ratios MASLD 0.96 (95% CI: 0.82, 1.12) second quartile, 0.80 0.68, 0.95) third quartile 0.60 0.49, 0.73) fourth respectively. CDAI, however, not significantly Conclusion These findings suggested that scores on linearly negatively United States adults.

Language: Английский

---

Sarcopenia in MASLD—Eat to Beat Steatosis, Move to Prove Strength

Nutrients, Journal Year: 2025, Volume and Issue: 17(1), P. 178 - 178

Published: Jan. 2, 2025

The connections between sarcopenia and various chronic conditions, including type 2 diabetes (T2DM), metabolic syndrome (MetS), liver disease have been highlighted recently. There is also a high occurrence of in dysfunction-associated steatotic (MASLD) patients, who are often disregarded. Both experimental clinical findings suggest complex, bidirectional relationship MASLD sarcopenia. While vitamin D, testosterone, specific drug therapies show promise mitigating sarcopenia, consensus on effective treatments lacking. Recent focus lifestyle interventions emphasizes dietary therapy exercise for sarcopenic obesity MASLD. Challenges arise as weight loss, primary treatment, may lead to muscle mass reduction. therapeutic approach morbidly obese patients includes bariatric surgery (BS). BS induces loss stabilizes imbalances, but its impact nuanced, underscoring the need further research. Our aim provide comprehensive review interplay offer insight into most recent challenges discoveries, overlooked or unrecognized poses significant managing these patients.

Language: Английский

---

Association of pan-immune-inflammatory value with metabolic dysfunction-associated steatotic liver disease: findings from NHANES 2017–2020

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 3, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic worldwide. The pan-immune-inflammation value (PIV) been proposed as a biomarker for assessing immune status and inflammation. There is currently no evidence regarding effect of PIV on risk MASLD. This study aimed to investigate association between cross-sectional included 6462 adults aged ≥ 20 years from National Health Nutrition Examination Survey 2017–2020. was calculated based blood count data. Weighted multivariable logistic regression employed calculate odds ratio (OR) 95% confidence interval (CI) Restricted cubic spline (RCS) analysis conducted explore dose-response relationship Stratified sensitivity analyses were performed confirm robustness our findings. Among participants, 2458 diagnosed with Positive associations LnPIV MASLD observed in all three models (Model 1: OR = 1.46, CI: 1.28–1.66, P < 0.001; Model 2: 1.41, 1.24–1.60, 3: 1.39, 1.16–1.65, 0.004). When classified into quartiles, both Q3 Q4 exhibited significantly increased risks compared reference Q1 full adjusted 3 (Q3: 1.63, 1.20–2.22, 0.012; Q4: 1.76, 1.28–2.41, 0.008; trend 0.002). RCS did not show nonlinear (P 0.093 nonlinearity). showed consistent positive subgroups, supported reliability these results. Higher levels are associated an prevalence MASLD, indicating that potentially effective inflammatory marker participants.

Language: Английский

---

Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD

Antioxidants, Journal Year: 2025, Volume and Issue: 14(1), P. 56 - 56

Published: Jan. 6, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic condition marked by excessive lipid accumulation in hepatic tissue. This disorder can lead to range of pathological outcomes, including metabolic steatohepatitis (MASH) and cirrhosis. Despite extensive research, the molecular mechanisms driving MASLD initiation progression remain incompletely understood. Oxidative stress peroxidation are pivotal "multiple parallel hit model", contributing cell death tissue damage. Gut microbiota plays substantial role modulating oxidative through multiple pathways: impairing intestinal barrier, which results bacterial translocation inflammation; modifying bile acid structure, impacts signaling cascades involved lipidic metabolism; influencing hepatocytes' ferroptosis, form programmed death; regulating trimethylamine N-oxide (TMAO) activating platelet function, both recently identified as pathogenetic factors MASH progression. Moreover, various exogenous impact gut its involvement MASLD-related stress, such air pollution, physical activity, cigarette smoke, alcohol, dietary patterns. manuscript aims provide state-of-the-art overview focused on intricate interplay between microbiota, peroxidation, pathogenesis, offering insights into potential strategies prevent associated complications.

Language: Английский

---

Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2959 - 2959

Published: March 25, 2025

Metabolic-dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is a highly prevalent metabolic disorder characterized by hepatic steatosis in conjunction with at least one cardiometabolic risk factor, such obesity, type 2 diabetes, hypertension, or dyslipidemia. As global rates of obesity and syndrome continue to rise, MASLD becoming major public health concern, projections indicating substantial increase prevalence over the coming decades. The spectrum ranges from simple metabolic-dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, hepatocellular carcinoma, contributing significant morbidity mortality worldwide. This review delves into molecular mechanisms driving pathogenesis, including dysregulation lipid metabolism, chronic inflammation, oxidative stress, mitochondrial dysfunction, gut microbiota alterations. Recent advances research have highlighted role genetic epigenetic factors progression, well novel therapeutic targets peroxisome proliferator-activated receptors (PPARs), fibroblast growth factors, thyroid hormone receptor beta agonists. Given multifaceted nature MASLD, multidisciplinary approach integrating early diagnosis, insights, lifestyle interventions, personalized therapies critical. underscores urgent need for continued innovative treatment strategies precision medicine approaches halt progression improve patient outcomes.

Language: Английский

---

Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases

Biomolecules, Journal Year: 2025, Volume and Issue: 15(1), P. 121 - 121

Published: Jan. 14, 2025

Chronic hepatobiliary damage progressively leads to fibrosis, which may evolve into cirrhosis and/or hepatocellular carcinoma. The fight against the increasing incidence of liver-related morbidity and mortality is challenged by a lack clinically validated early-stage biomarkers limited availability effective anti-fibrotic therapies. Current research focused on uncovering pathogenetic mechanisms that drive liver fibrosis. Drugs targeting molecular pathways involved in chronic diseases, such as inflammation, hepatic stellate cell activation proliferation, extracellular matrix production, are being developed. Etiology-specific treatments, those for hepatitis B C viruses, already clinical use, efforts develop new, targeted therapies other diseases ongoing. In this review, we highlight major changes occurring patients affected metabolic dysfunction-associated steatotic disease, viral (Delta virus), autoimmune (autoimmune hepatitis, primary biliary cholangitis, sclerosing cholangitis). Further, describe how knowledge linked current well ongoing preclinical novel strategies, including nucleic acid-, mesenchymal stromal/stem cell-, vesicle-based options. Much development obviously still missing, but plethora promising potential treatment strategies holds promise future reversal increase group patients.

Language: Английский

---

Characteristics of different lipid droplet-mitochondrial contacts patterns during lipid droplet metabolism in T2DM-induced MASLD

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 27, 2025

Mitochondrial function is crucial for hepatic lipid metabolism. Current research identifies two types of mitochondria based on their contact with droplets: peridroplet (PDM) and cytoplasmic (CM). This work aimed to investigate the alterations CM PDM in metabolic dysfunction-associated steatotic liver disease (MASLD) induced by spontaneous type-2 diabetes mellitus (T2DM) db/db mice. It was found that insulin resistance increased both number size droplets enhancing accumulation free fatty acids, which accompanied an increase contacts mitochondria. We described different patterns tight between small purified examining oxidation states morphological characteristics. In CM, enhanced acid resulted elongated surrounded single were responsible droplet consumption, while PDM, substrates synthesis promoted expansion assistance endoplasmic reticulum. These data show ways mitochondrial could provide new insights future

Language: Английский

---

Muscle Strength and Cardiovascular Health in MASLD: A Prospective Study

Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 247 - 247

Published: Feb. 1, 2025

Background and Objectives: The pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) remains incompletely understood. However, recent studies highlight the interactions between muscle, liver, adipose tissue. This study aimed to explore relationships clinical indicators MASLD sarcopenia, cardiorespiratory fitness, fatigue, mood. Materials Methods: involved 60 participants, including 28 healthy controls 32 with MASLD, categorized into two subgroups: 15 MASL 17 steatohepatitis (MASH). Participants completed an incremental speed shuttle walk test evaluate a hand-held dynamometer assessment for appendicular muscle strength, timed up go physical performance. Physical activity level, quality life, emotional state were assessed using questionnaires. results compared groups characteristics. Results: MASH showed reduced fitness (p < 0.001). knee extensors significantly weaker in both 0.001 p = 0.001, respectively). group reported higher levels depression negative health perception 0.006 0.03, Muscle strength patients significant association (OR −0.384, 95% CI: −3.10 −0.74, 0.003), intrahepatic triglyceride content −0.287, −1.31 −0.11, 0.023), LDL −0.286, −0.02 −0.33, 0.03). In contrast, positive was observed VO2 0.531, CI 1.27 3.47, Conclusions: suggests that is linked key parameters, such as hepatic fat, levels, aerobic capacity, may contribute development progression MASLD. Interventions at preserving or enhancing be essential preventing damage improving health.

Language: Английский

---

The obesity pandemic and its impact on non-communicable disease burden

Pflügers Archiv - European Journal of Physiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 10, 2025

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management

Exploration of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging and rapidly growing health problem that currently affects more than one-third of the world general population two-thirds patients with obesity or type 2 diabetes. MASLD associated one cardio-metabolic risk factors (CMRFs) determine complexity its natural history management. Although term encompasses a single disease, each CMRF has different impact on MASLD, number overlapping CMRFs results in rate progression outcomes both systemic disease. Its pathogenesis characterized by insulin resistance, lipotoxicity complex cross-talk between liver, adipose tissue, muscle, intestine through release hepatokines, cytokines, myokines inflammatory products. The stage fibrosis best predictor outcomes, such as failure mortality, also predicts high all-cause mortality In many cases, development hepatocellular carcinoma (HCC) advanced cirrhosis, although it can occur at all stages making prevention difficult. increasing very low-density lipoprotein (VLDL) secretion chronic low-grade inflammation, which increase cardio-vascular, renal, endocrine diseases extrahepatic cancer. Thus, management requires holistic approach treatment multispecialty collaboration. Currently, diet physical activity are effective first-line approaches. There no approved drugs for apart from resmetirom, percentage cases improves metabolic steatohepatitis (MASH) fibrosis. We summarize wide varied recent literature etiopathogenetic, clinical therapeutic aspects connecting interpreting to facilitate

Language: Английский

---